Aimmune Therapeutics Annual Revenue, Number of Employees, Growth and Funding
Navigation
Overview
City Ranking
Industry Ranking
State Ranking
Growjo 10k Ranking
Estimated Revenue & Financials
- Aimmune Therapeutics's estimated annual revenue is currently $30.7M per year.
- Aimmune Therapeutics received $170.0M in venture funding in January 2019.
- Aimmune Therapeutics's estimated revenue per employee is $102,642
- Aimmune Therapeutics's total funding is $398.7M.
Employee Data
- Aimmune Therapeutics has 299 Employees.
- Aimmune Therapeutics grew their employee count by 20% last year.
- Aimmune Therapeutics currently has 56 job openings.
Executive Contacts
| Name | Title |
|---|---|
| Daniel Adelman | Chief Medical Officer |
| Stuart Donaldson | Director, Clinical Data Management |
| Sri Ryali | Vice President Finance |
| Azadeh Nolan | Director, Clinical Supply Chain Operations |
| Jovon Milam | Director, Midwest Region |
| Renee Bower | Associate Director Clinical Quality Assurance |
| Colleen Hansen | Vice President Quality Assurance |
| Paul Jedrzejewski | Sr. Director, Analytical Development and Quality Control |
| Joseph Niemann | Associate Director Process Development and Commercialization |
| Jerry Castro | Associate Director, Commercial Supply Chain |
What Is Aimmune Therapeutics?
Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy. Aimmune is located in Brisbane, California - the heart of San Francisco's biotechnology hub - with additional offices in the Kings Cross area of London and in Raleigh, North Carolina.
keywords:Biotechnology,Food & Beverages,Healthcare,Pharmaceuticals299
Number of Employees
$30.7M
Revenue (est)
56
Current Jobs
20%
Employee Growth %
$398.7M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Similar Companies
| Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
| $6.2M | 43 | 10% | N/A | |
| $10.7M | 74 | 45% | N/A | |
| $42M | 290 | 4% | N/A | |
| $26.4M | 182 | 3% | N/A | |
| $5.9M | 41 | 37% | N/A | |
| $25.7M | 178 | 8% | N/A | |
| $5.7M | 40 | 11% | N/A | |
| $4.2M | 33 | -15% | N/A | |
| $6M | 42 | 5% | N/A | |
| $7.1M | 49 | -2% | N/A |
Aimmune Therapeutics News
13, will be a pivotal moment for Aimmune Therapeutics (AIMT 5), the biopharma company that developed the new treatment, called AR101.
BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food ...
Operator. Good afternoon, ladies and gentlemen, and welcome to the Aimmune Therapeutics, Second Quarter 2019 Earnings Conference Call.
Aimmune Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-11-07 | $145.0M | Nestlé Health Scienc | Nestlé Health Science | Article |
| 2018-02-21 | $177.5M | Undisclosed | Article | |
| 2018-11-29 | $98.0M | Undisclosed | Nestlé Health Science | Article |
| 2019-01-07 | $170.0M | Undisclosed | KKR | Article |
Aimmune Therapeutics Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2015-10-12 | Howard Raff | Consultant | Article |
| 2016-04-06 | Douglas Sheehy | General Counsel/Secretary | Article |
| 2016-06-22 | Daniel Adelman | Chief Medical Officer | Article |
| 2017-04-14 | Eric Bjerkholt | Chief Financial Officer | Article |
| 2018-06-12 | Jayson Dallas | President and Chief Executive Officer | Article |
| 2019-01-21 | Andrew Oxtoby | Chief Commercial Officer | Article |